---
document_datetime: 2023-09-21 20:17:27
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/panretin-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: panretin-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.5019628
conversion_datetime: 2025-12-19 00:01:12.915325
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Panretin

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended no   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IAIN/0045            | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 24/01/2019 product                  | on                                          | Annex II and PL                  |           |
| IAIN/0044            | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer                                                                                        | 24/01/2019                          | n/a                                         |                                  |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

Medicinal product no longer authorised

<!-- image -->

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |                                         |                                                                                   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----------------------------------------|-----------------------------------------------------------------------------------|
| T/0043    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 19/11/2018 | 20/12/2018 SmPC, Labelling PL           | and authorised                                                                    |
| IAIN/0042 | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 04/07/2018 | n/a                                     |                                                                                   |
| A31/0037  | Pursuant to Article 31 of Directive 2001/83/EC, the United Kingdom triggered on 7 July 2016 a referral resulting from pharmacovigilance data, and requested the PRAC to review the routine risk minimisation in place for the oral and topical retinoids to ensure the available data and the risks associated with the adverse teratogenic effects and neuropsychiatric disorders are accurately and consistently addressed within the product information where appropriate and justified by data. Furthermore, the PRAC was requested to review any additional risk minimisation measures to ensure that these are optimal in terms of provision of information and delivery of effective risk management that is subject to appropriate monitoring. The PRAC was called upon to assess the impact of the above concerns on the benefit-risk balance of retinoid-containing medicinal products and issue a recommendation on whether the products should be maintained, varied, suspended or revoked. Medicinal product | 22/03/2018 | 21/06/2018 SmPC, Annex and PL no longer | II Please refer to the assessment report: Panretin EMEA/H/A-31/1446/C/000279/0037 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                  | As the request resulted from the evaluation of data resulting from pharmacovigilance activities, the PRAC issued a recommendation to the Committee for Medicinal Products for Human Use (CHMP).                                              |                    |                                | authorised                        |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|--------------------------------|-----------------------------------|
| N/0040           | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                             | 22/11/2017         | 21/06/2018 PL                  |                                   |
| PSUSA/90/20 1701 | Periodic Safety Update EU Single assessment - alitretinoin                                                                                                                                                                                   | 01/09/2017         | n/a longer                     | PRAC Recommendation - maintenance |
| IA/0039          | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 03/08/2017         | n/a no                         |                                   |
| PSUSA/90/20 1601 | Periodic Safety Update EU Single assessment - alitretinoin                                                                                                                                                                                   | 02/09/2016         |                                | PRAC Recommendation - maintenance |
| IA/0035          | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                | 16/09/2015 product | n/a 08/09/2016 Annex II and PL |                                   |
| IAIN/0034        | B.II.d.1.h - Change in the specification parameters and/or limits of the finished product - Update of the dossier to comply with the provisions of an updated general monograph of the Ph. Eur. for the finished product Medicinal           | 17/11/2014         | n/a                            |                                   |

<div style=\"page-break-after: always\"></div>

| N/0033    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 04/11/2014   | 08/09/2016    | PL                |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|-------------------|
| IB/0032/G | This was an application for a group of variations. B.II.b.4.z - Change in the batch size (including batch size ranges) of the finished product - Other variation B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch-release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site | 25/10/2013   | n/a           | longer authorised |
| IB/0031   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) product                                                                                                                                                                                                                                                                                                                                                                                                                                  | 07/10/2013   | 19/08/2014 no | SmPC              |
| IG/0345   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                                                                                                    | 03/09/2013   | n/a           |                   |
| N/0028    | The MAH applied to change the details of the local representative for France. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) Medicinal                                                                                                                                                                                                                                                                                                                                                                                           | 08/07/2013   | 19/08/2014    | PL                |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IAIN/0029   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 20/05/2013   | n/a                 |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------------|
| N/0027      | Update of the local representatives contact details. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 07/08/2012   | 19/08/2014 PL       |
| IAIN/0026   | A.5.a - Administrative change - Change in the name and/or address of a manufacturer responsible for batch release                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 20/01/2012   | 23/08/2012 Annex II |
| IAIN/0025/G | This was an application for a group of variations. A.5.a - Administrative change - Change in the name and/or address of a manufacturer responsible for batch release B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State Medicinal product | 16/12/2011   | n/a no longer       |

<div style=\"page-break-after: always\"></div>

| R/0024   | Renewal of the marketing authorisation.                                                                                                                                   | 22/07/2010   | 27/09/2010   | SmPC, Annex II, Labelling and PL   | Based on the CHMP review of the available information and on the basis of a re-evaluation of the benefit risk balance, the CHMP is of the opinion that the quality, safety and efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and therefore considered that the benefit risk profile of Panretin continues to be favourable. The CHMP recommends the renewal of the Marketing Authorisation for Panretin, subject to the conditions as laid down in Annex II to the Opinion as well as the commitments of the Marketing Authorisation Holder as laid down in his Letter of Undertaking (see Attachment 4 of this Assessment Report). The CHMP is also of the opinion that the renewal can be granted with unlimited validity. authorised   |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0023   | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                          | 07/05/2010   | n/a no       | PL longer                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IA/0022  | To add Eisai B.V as a new manufacturing site for QP batch release activities regarding Panretin finished product. IA_08_b_01_Change in BR/QC testing - repl./add. product | 21/12/2009   | n/a          | PL                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IA/0021  | manuf. responsible for BR - not incl. BC/testing IA_01_Change in the name and/or address of the marketing authorisation holder Medicinal                                  | 06/04/2009   | n/a          | SmPC, Labelling and PL             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IB/0020  | IB_29_a_Change in qual./quant. composition of immediate packaging - semi-solid/liquid ph. forms                                                                           | 27/03/2009   | n/a          |                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| IA/0019   | IA_08_b_01_Change in BR/QC testing - repl./add. manuf. responsible for BR - not incl. BC/testing           | 05/02/2009         | n/a        | Annex II and PL                  |                                                                                                                                                                                                                                                                                                            |
|-----------|------------------------------------------------------------------------------------------------------------|--------------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0018    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)           | 14/10/2008         | n/a        | PL                               |                                                                                                                                                                                                                                                                                                            |
| T/0017    | Transfer of Marketing Authorisation Transfer of Marketing Authorisation                                    | 16/03/2007         | 11/04/2007 | SmPC, Labelling and PL           | The MAH applied for a transfer of the Marketing Authorisation from 'Ligand Pharmaceuticals UK Ltd' to 'Eisai Ltd'. The MAH also took the opportunity to update the Annexes in compliance with the latest QRD template 7.2. authorised                                                                      |
| IA/0016   | IA_05_Change in the name and/or address of a manufacturer of the finished product                          | 19/01/2007         | n/a        | Annex II and PL longer           |                                                                                                                                                                                                                                                                                                            |
| IB/0015   | IB_14_b_Change in manuf. of active substance without Ph. Eur. certificate - new manufacturer               | 04/01/2007         | n/a        |                                  |                                                                                                                                                                                                                                                                                                            |
| N/0014    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)           | 23/01/2006         | n/a no     | PL                               |                                                                                                                                                                                                                                                                                                            |
| IA/0013   | IA_05_Change in the name and/or address of a manufacturer of the finished product                          | 16/12/2005 product | n/a        |                                  |                                                                                                                                                                                                                                                                                                            |
| R/0012    | Renewal of the marketing authorisation.                                                                    | 15/09/2005         | 17/11/2005 | SmPC, Annex II, Labelling and PL | Based on the review of the available information the CHMP is of the opinion that the quality, the safety and the efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and therefore considers that the benefit/risk profile of Panretin continues to be favourable. |
| N/0011    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) Medicinal | 23/05/2005         | n/a        | PL                               |                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| IA/0009   | IA_05_Change in the name and/or address of a manufacturer of the finished product                | 23/03/2004         | n/a           | Annex II and PL        |
|-----------|--------------------------------------------------------------------------------------------------|--------------------|---------------|------------------------|
| N/0008    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 15/05/2003         | 11/06/2003    | PL                     |
| N/0007    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 13/02/2003         | 10/04/2003    | PL authorised          |
| I/0006    | 15_Minor changes in manufacture of the medicinal product                                         | 04/02/2003         | 07/02/2003    |                        |
| I/0005    | 16_Change in the batch size of finished product                                                  | 04/02/2003         | 07/02/2003    |                        |
| I/0004    | 01_Change in or addition of manufacturing site(s) for part or all of the manufacturing process   | 04/02/2003         | 07/02/2003 no | longer                 |
| I/0002    | 03_Change in the name and/or address of the marketing authorisation holder                       | 11/06/2002         | 10/07/2002    | SmPC, Labelling and PL |
| N/0001    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 13/07/2001 product | n/a           | Labelling and PL       |

Medicinal product no longer authorised